Lucinactant approved to treat breathing distress

Article

The US Food and Drug Administration has approved lucinactant, a new surfactant that prevents respiratory distress syndrome, most common in babies born 6 weeks or more before their due dates.

The US Food and Drug Administration (FDA) has approved lucinactant, a new surfactant that prevents respiratory distress syndrome (RDS), most common in babies born 6 weeks or more before their due dates.

A single multidose study proved lucinactant's safety and efficacy compared with other FDA-approved surfactants. In the study, 1,294 premature infants were given lucinactant, colfosceril palmitate, or beractant within 30 minutes of birth. The infants who received lucinactant demonstrated significant improvement in RDS at 24 hours and in RDS-related mortality through 2 weeks compared with infants who received the other surfactants.

The most common side effects of lucinactant are related to administration through the infant's endotracheal tube and include tube reflux or obstruction, pale skin, and dose interruption.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.